S27 - "Best Of" Session: Neuromuscular Disease Therapeutics

Event Time: Wednesday April 26, 2017 8:00 am to 9:00 am
Topic(s): Neuromuscular and Clinical Neurophysiology (EMG)
Director(s):
Description: A platform session that brings together the top four scoring abstracts in a particular topic, as rated by the topic reviewers. Offers an opportunity to interact with the author in a smaller setting at the conclusion of the session.
Completion Message:
CME Credits: 1
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
8:00 AM 001 Rasagiline for the Treatment of ALS: a randomized controlled study Richard Barohn, MD, FAAN
Disclosure:
Dr. Barohn has nothing to disclose.

8:08 AM 002 Oral Fingolimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (FORCIDP): Results from a Phase III Randomized Placebo-controlled Trial Hans-Peter Hartung, MD, FAAN
Disclosure:
Dr. Hartung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, GeNeuro, Sanofi Genzyme, Merck, Novartis Pharmaceuticals, Octapharma, Opexa Therapeutics, Teva Pharmaceuticals, MedImmune, Bayer HealthCare, Forward Pharma, and Roche.

8:16 AM 003 AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Interim Data Demonstrates Improvements in Supportive Care Use Jerry Mendell, MD, FAAN
Disclosure:
Dr. Mendell has received research support from Investigator in clinical studies funded by AveXis, Inc..

8:24 AM 004 Phase 2 Open-Label Extension (OLE) Study of Patisiran, an Investigational RNA interference (RNAi) Therapeutic for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy David Adams
Disclosure:
Dr. Adams has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Alnylam, Prothena. Dr. Adams has received research support from Ionis, Alnylam.

Register Now

Related Courses